May 9, 2016 (GLOBE NEWSWIRE) – Novastep, Inc., and its affiliates (“Novastep” or the “Company”), a global medical technologies company specializing in foot and ankle implants, biologics, instrument systems and medical education programs, today announced its entry into an agreement with VIVEX Biologics, Inc., a privately held company focused on cellular therapies that treat orthopaedic, spine, wound and soft tissue indications.

With this new relationship, Novastep gains access to VIVEX’ catalog of allograft materials. In particular, Novastep’s new family of biologics products, marketed under the name bioSTART® Tissue Repair Process, will allow Novastep to immediately offer amniotic membranes and liquid to surgeons performing foot and ankle procedures in clinical and outpatient settings throughout the United States. The Company is likewise expanding its portfolio to add demineralized bone matrices, geometrically configured bone wedges and other biologics materials to its product offering.

“This agreement reflects Novastep’s commitment to offer surgeon users differentiated technologies that target bone, joint and soft tissue disorders of the foot and ankle for the benefit of their patients,” said Vadim Gurevich, President and CEO of Novastep, Inc. “We are extremely pleased to be working with VIVEX, not only because our respective competencies complement each other so elegantly, but also because of the broad range of benefits our relationship will bring to the patient population as a whole,” added Gurevich.

“Associations with pioneering industry leaders like Novastep furthers our commitment to clinicians by helping donated tissue reach more patients,” said Tracy Anderson, President and CEO of VIVEX Biologics. “We look forward to growing our relationship with Novastep.”

Novastep is broadening their scope of surgeon education, sales training and scientific discussion forum programs to help support this market entry. In line with this added emphasis, Novastep’s annual Global Foot and Ankle Symposium (GFAS), being held on December 2 – 3 in New York City will feature an expanded biologics session.

About Novastep Inc.
Novastep Inc., (www.novastep-us.com) is a global medical device company specializing in the design, development and commercialization of advanced technologies that treat conditions affecting the foot and ankle. The Company is focused to optimize clinical efficiencies, inventory management and healthcare economics by transforming the way foot and ankle products are deployed and utilized in the surgical environment.  Novastep has allied itself with a strategic network of key international opinion leaders to deliver breakthrough technologies, innovative services and compelling medical education programs to the foot and ankle community.

About VIVEX Biologics, Inc.
VIVEX Biologics, Inc., (www.vivex.com) is a privately held company based out of Marietta, Georgia focused on cellular therapies that treat orthopaedic, spine, wound and soft tissue indications. VIVEX Biologics and its wholly owned subsidiary, VIVEX Biomedical, Inc., own and hold exclusive rights to proprietary technologies in the field of biomedicine, stem cells, and orthopaedic implant surface modification. The VIVEX Biologics technology includes marrow isolated adult multilineage inducible (MIAMI) cell identification and processing, as well as, mimetic patterning technologies (MIME) which can improve the efficiency and efficacy of a patient’s healing cascade and reduce the overall cost of healthcare.

For further information concerning this announcement and/or Novastep, Inc., send all inquiries to info@novasteportho.com or call 877.287.0795.
Related Links:
novastep-us.com

PARSIPPANY, N.J., April 19, 2016 /PRNewswire/ — Onkos Surgical and VIVEX Biologics, Inc. have come together to provide a portfolio of tissue products to support the needs of musculoskeletal oncologists and their patients. This commitment strengthens Onkos Surgical’s ability to enhance outcomes, decrease complications and improve recovery following musculoskeletal tumor and limb salvage surgery.

BELGRADE, Mont., March 24, 2016 EconoTimes — Xtant Medical Holdings, Inc. (NYSE:XTNT), a leader in the development of regenerative medicine products and medical devices, is expanding its biologics portfolio through a distribution relationship with VIVEX Biologics, Inc., a leading processor of human tissue, synthetics, mimetic patterning technology, and biocellular products. Through this agreement, Xtant Medical will be entering the cellular bone graft market with a viable cell allograft, OsteoVive™.

VIVEX Biologics’s proprietary process preserves a cell population that includes marrow-isolated adult multilineage inducible (MIAMI) cells. These cells have been shown to support the patient’s innate bone healing process. VIVEX will process the allograft for Xtant Medical, and Xtant Medical will provide national distribution, focused on spine and orthopedics, through its sales channels and extensive, national contract networks.

“VIVEX is enthusiastic about teaming up with Xtant Medical, a leading distributor of biologics products,” said Tracy Anderson, CEO of VIVEX Biologics. “Working closely with leading biologics distributors like Xtant Medical helps further our mission of enhancing patient care by expanding industry knowledge and capability.”

This relationship allows Xtant Medical to immediately enter the cellular bone graft market with a differentiated product. According to BioMedGPS, it estimates the cellular allograft market was approximately $252MM in 2015, and is anticipated to be near $400MM in 2019, making it the fastest growing segment of the bone replacement market.

“We are pleased to be adding this distinguished viable cell allograft to our biologic portfolio,” said Dan Goldberger, CEO of Xtant Medical. “The addition of OsteoVive will allow us to better meet the preferences of our surgeons, and will increase the value we are able to deliver to our customers.”

About Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. (NYSE:XTNT) develops, manufactures and markets class-leading regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further information, please visit www.xtantmedical.com.

About VIVEX Biomedical, Inc.

VIVEX Biologics is a privately held company based out of Marietta, Georgia focused on cellular therapies that treat orthopaedic, spine, wound and soft tissue indications. VIVEX and its wholly owned subsidiary, VIVEX Biomedical, Inc., own and hold exclusive rights to proprietary technologies in the field of biomedicine, stem cells, and orthopaedic implant surface modification. The VIVEX Biologics technology includes marrow isolated adult multilineage inducible (MIAMI) cell identification and processing, as well as, mimetic patterning technologies (MIME) which can improve the efficiency and efficacy of a patient’s healing cascade and reduce the overall cost of healthcare.

About VIVEX Biomedical, Inc.

Founded in 1970 through a partnership with the U.S. Naval Hospital in Bethesda, MD, the University of Miami Tissue Bank (“UMTB”) is the oldest tissue bank in the United States. UMTB was acquired November of 2014 by VIVEX Biomedical, Inc., a wholly owned subsidiary of VIVEX Biologics. UMTB has been led by H. Thomas Temple, M.D., a world renowned orthopaedic oncologist and surgeon.

Important Cautions Regarding Forward-looking Statements

This press release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “continue,” “efforts,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “projects,” “forecasts,” “strategy,” “will,” “goal,” “target,” “prospects,” “potential,” “optimistic,” “confident,” “likely,” “probable” or similar expressions or the negative thereof.  Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company’s ability to successfully integrate the acquisition of X-spine; the ability of the Company’s sales force to achieve expected results, the Company’s ability to meet its existing and anticipated contractual obligations, including financial covenant and other obligations contained in the Company’s secured lending facility; the Company’s ability to manage cash flow; the Company’s ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company’s customers to pay and the timeliness of such payments; the Company’s ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company’s ability to attract and retain management and employees with appropriate skills and expertise; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the heading “Risk Factors.” You should carefully consider the trends, risks and uncertainties described in this document, the Form 10-K and other reports filed with or furnished to the SEC before making any investment decision with respect to our securities. If any of these trends, risks or uncertainties actually occurs or continues, our business, financial condition or operating results could be materially adversely affected, the trading prices of our securities could decline, and you could lose all or part of your investment. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.

MARIETTA, Ga., March 17, 2016 /PRNewswire/ — VIVEX Biologics, Inc., a leading processor of human tissue, synthetics, mimetic patterning technology, and biocellular products, announced today that its subsidiary, VIVEX Biomedical, Inc., hired Dave Fronk as Vice President of Quality Systems and promoted Dr. Shabnam Namin to Vice President of Research and Development.   VIVEX Biologics formed UMTB Biomedical as a wholly-owned subsidiary to acquire theUniversity of Miami Tissue Bank (UMTB) in November 2014.  UMTB is the oldest tissue bank in the country.

David M. Fronk joined VIVEX Biomedical, Inc. in December 2015, as Vice President of Quality Systems.  Dave has 30 years of experience within the medical device industry, including 23 years of experience in the tissue banking industry.  Prior to joining UMTB Biomedical, he held Regulatory, Quality, and Clinical Research executive management positions at CryoLife, Inc., a leading processor of cardiovascular human tissue and medical device manufacturer located inAtlanta, Georgia.    Previous to this, he held various orthopaedic product development positions at Baxter Healthcare Corporation and Zimmer, Inc.  He received both his B.S. in mechanical engineering and his M.S. in biomedical engineering from the Ohio State University.

Dr. Shabnam Namin joined UMTB three years ago and has successfully and progressively led the Research and Development team at UMTB Biomedical, most recently launching four new products and five new line extensions.  She has been responsible for leading product development of all cell and tissue based product for the company.  In addition, Dr. Namin is an important member of the commercialization team with a main interest in the development of regenerative therapies.  Prior to joining UMTB, Dr. Namin earned her PhD in Biomedical Engineering from Florida International University.  She also received an MBA and MS in Industrial Engineering from the University of Miami.  During her studies, Dr. Namin spent several years working in many different facets in the tissue engineering realm, focusing on the commercialization of cell and tissue based products.  She has multiple publications and patents for her work on the development of these therapies.  She is currently an active member of both the Birth Tissue Committee as well as the Scientific & Technical Affairs Committee (STAC) for the American Association of Tissue Banks.

“As we continue to strengthen the quality of our management team, we seek out the best and the brightest in the industry.  Dave and Dr. Namin fit that bill perfectly. They are among the best in their respective fields and we are truly excited about the work that they have already begun to do to further our mission to be the premier biomedical company in the country,” stated Tracy Anderson, President & CEO VIVEX Biologics, Inc.

“The caliber of Dave & Dr. Namin add significant capabilities to our team.  Their skill sets complement those on our team and position VIVEX Biologics and UMTB Biomedical as an emerging leader in our industry,” says Lou Barnes, President & COO VIVEX Biomedical, Inc.

About VIVEX Biologics, Inc.: VIVEX Biologics is a privately held company based out of Marietta, Georgia focused on biologically active tissue forms that treat orthopaedic, spine, wound and soft tissue indications. VIVEX and its wholly owned subsidiary, VIVEX Biomedical, Inc., own and hold exclusive rights to proprietary technologies in the field of biomedicine, stem cells, and orthopaedic implant surface modification. The VIVEX Biologics technology includes marrow isolated adult multilineage inducible (MIAMI) cell identification and processing, as well as, mimetic patterning technologies (MIME) which can improve the efficiency and efficacy of a patient’s healing cascade and reduce the overall cost of healthcare.

About VIVEX Biomedical, Inc.: Founded in 1970 through a partnership with the U.S. Naval Hospital in Bethesda, MD, the University of Miami Tissue Bank (“UMTB”)  is the oldest tissue bank in the United States.  UMTB was acquired November of 2014 by VIVEX Biomedical, Inc., a wholly owned subsidiary of VIVEX Biologics.  UMTB has been led by H. Thomas Temple, M.D., a world renowned orthopaedic oncologist and surgeon.

Safe Harbor Statements. This press release contains forward-looking statements. These forward-looking statements are based on our current assumptions, expectations, and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties, and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, without limitation, factors affecting our financial results, demand for our products, our ability to obtain regulatory clearance or approval, where necessary, from the U.S. Food and Drug Administration, our ability to compete successfully, our ability to safeguard our intellectual property, and our ability to comply with laws and regulations that are or may become applicable to our businesses. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements.

VIVEX Biologics, Inc., a leading processor of human tissue, synthetics, mimetic patterning technology, and biocellular products, announced today that it hired Lou Barnes as President and Chief Operating Officer of VIVEX Biomedical, Inc. VIVEX Biologics formed UMTB Biomedical as a wholly-owned subsidiary to acquire the University of Miami Tissue Bank (UMTB) in November 2014. UMTB is the oldest tissue bank in the country.

Mr. Barnes is a twenty-five year veteran of the tissue banking industry, having most recently served as Executive Director of DCI Donor Services Tissue Bank, Inc. in Nashville, Tennessee. Prior to DCI, Mr. Barnes worked with other leading tissue banks, both in the for-profit and not-for-profit sectors. Mr. Barnes is the current Chair of American Association of Tissue Banks (AATB) Processing & Distribution Council and a member of AATB’s Board of Governors.

“We are extremely excited to have Lou and his wife, Teri, join the VIVEX family of companies. His leadership skills and high level of expertise add to the growing pool of talent we are bringing to our tissue bank in Miami, Florida,” stated Tracy Anderson, President and CEO of VIVEX Biologics, Inc.

Regarding his new role, Mr. Barnes states, “This is an exciting opportunity to join VIVEX Biologics, a leading company in the tissue banking industry, and work with a talented team to bring new allograft forms to patients in need. VIVEX develops technology platforms that will maximize the gift of tissue donation through advancements in regenerative medicine.”

Comments and questions for VIVEX can be directed to Michael Rozmajzl, General Counsel, at (770) 575‐ 5221.

About VIVEX: VIVEX Biologics, Inc. is a privately held company based out of Marietta, Georgia focused on cellular therapies that treat orthopaedic, spine, wound and soft tissue indications. VIVEX and its wholly owned subsidiary, UMTB Biomedical, own and hold exclusive rights to proprietary technologies in the field of biomedicine, stem cells, and orthopaedic implant surface modification. The VIVEX Biologics technology includes marrow isolated adult multilineage inducible (MIAMI) cell identification and processing, as well as, mimetic patterning technologies (MIME) which can improve the efficiency and efficacy of a patient’s healing cascade and reduce the overall cost of healthcare.

About UMTB: Founded in 1970 through a partnership with the U.S. Naval Hospital in Bethesda, MD, the UMTB tissue bank is the oldest tissue bank in the United States. VIVEX Biologics and UMTB Biomedical maintain a close working relationship with the University of Miami in the field of tissue banking. UMTB has been led by H. Thomas Temple, M.D., a world renowned orthopaedic oncologist and surgeon at the University of Miami.

Safe Harbor Statements. This press release contains forward-looking statements. These forward-looking statements are based on our current assumptions, expectations, and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties, and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, without limitation, factors affecting our financial results, demand for our products, our ability to obtain regulatory clearance or approval, where necessary, from the U.S. Food and Drug Administration, our ability to compete successfully, our ability to safeguard our intellectual property, and our ability to comply with laws and regulations that are or may become applicable to our businesses. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements.

VIVEX Biologics, Inc. Announces Definitive Agreement with the University of Miami Marietta, GA/Miami, FL

VIVEX Biologics, Inc. (“VIVEX”), a biomaterials manufacturer, distributor, and developer located in Marietta, Georgia, today announced that it has acquired certain assets and agreements of the University of Miami’s Tissue Bank (UMTB). Established in 1970, UMTB is the oldest and one of the most respected tissue banks in the United States. UMTB is a provider of human tissue and cellular products, including bone allografts, biomaterials, and soft tissue products for the spine, orthopedics, sports medicine, dental, and wound care markets.

“The strategic alliance with UMTB and the acquisition of their proprietary technology will complement VIVEX’s existing portfolio and represents a key step in fulfilling our strategy of building a broad business in the regenerative biologics sector,” said Tracy Anderson, CEO of VIVEX.
In this strategic alliance, VIVEX will maintain and expand upon the existing manufacturing and distribution agreements while the University of Miami will continue to build on its strong history and donor relationships with local hospitals and donor organizations.

“The University of Miami’s Tissue Bank has designed and manufactured tissue products that make a difference in people’s lives. In VIVEX, we have the right industry ally to carry on the tradition of commitment to serving patients and advancing science,” said Joe Natoli, Senior Vice President for Business & Finance and Chief Financial Officer of the University of Miami.

“As a surgeon, I could not be happier about the ally we have chosen, and I believe with this alliance we will achieve new heights in the fields of tissue regeneration,” said H. Thomas Temple, M.D., Director of the University of Miami’s Tissue Bank, professor and vice chair of orthopedics at the Miller School of Medicine. “Furthermore, I am most pleased with VIVEX management and the respect they have shown to the process of tissue donation and honoring the Gift of Life.”

VIVEX will continue existing tissue operations in Miami and has committed to expanding the resources available. “We are extremely excited to welcome the talented and dedicated employees of UMTB to the VIVEX family and we look forward to adding more in the weeks and months to come,” said Anderson.

Comments and questions for VIVEX can be directed to Michael Rozmajzl, General Counsel, at (770) 575- 5221 For University of Miami Miller School of Medicine inquiries, contact Lisa Worley at (305) 243-5184.

About VIVEX:

VIVEX Biologics, Inc. is a privately held, Marietta, GA based company focused in biologics and cellular therapies that treat orthopaedic, spine, wound and soft tissue injuries. VIVEX has proprietary technologies in the field of stem cells and implant surface modification. The marrow isolated adult multilineage inducible (MIAMI) cells and mimetic patterning technologies (MIME) will improve the healing environment for the patient and reduce the overall cost in the healthcare environment.

About UMTB

Founded in 1970 through a partnership with the U.S. Naval Hospital in Bethesda, MD, UMTB is the oldest tissue bank in the United States. In addition, it is the only tissue bank that has university ties to research as well as partnerships in donation. UMTB has been led by H. Thomas Temple, M.D., a world renowned orthopedic oncologist and surgeon at the University of Miami.

Safe Harbor Statements

Akron is pleased to announce that it secured an exclusive collaboration with VIVEX Biologics, Inc. on the use of its next-generation line of cryopreservation media, CryoNovo^TM.

VIVEX Biologics, Inc., from Marietta, GA, designs and develops innovative biologic products for regenerative medicine applications. Tracy Anderson, VIVEX CEO, speaks to the imperative,

“VIVEX underscores it commitment to patient care in the confidence that only the highest quality products become therapeutic options. Our collaboration with Akron Biotech meets those standards of excellence!”

Akron’s glycerol-, serum- and DMSO-free cryoprotectant, CryoNovo^TM T82, was developed as a non-toxic alternative to traditional DMSO-based cryopreservation media. CryoNovo^TM T82 provides improved cell viability and functionality when used to preserve of biological cells and tissues.

Akron’s Claudia Zylberberg said, “We are extremely pleased to extend our new line of DMSO-free cryomedia toward exciting and important new applications, and the collaboration with VIVEX is a prime example of the potential and significance of improved cryopreservation solutions which Akron pioneered.”

CryoNovo^TM T82 is used in the VIVEX process of viable bone allograft preparation; retaining cell function, sustaining cell viability, and providing dependable cell identity that supports therapeutic intervention in orthopaedic and other regenerative medicine applications.